Rocket Pharmaceuticals, Inc. is focused on developing first-in-class gene therapy treatment for rare and devastating diseases. Rocket’s multi-platform approach applies LVV and AAV gene therapy platforms. Our clinical programs are for Fanconi Anemia, Leukocyte Adhesion Deficiency-I and Danon disease. Rocket’s pre-clinical programs are Pyruvate Kinase Deficiency and Infantile Malignant Osteopetrosis.